Medications mostly associated with priapism events: assessment of the 2015-2020 Food and Drug Administration (FDA) pharmacovigilance database entries.

Autor: Schifano N; Università Vita-Salute San Raffaele, Milan, Italy.; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy., Capogrosso P; ASST Sette Laghi-Circolo e Fondazione Macchi Hospital, Varese, Italy., Boeri L; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy.; Department of Urology, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy., Fallara G; Università Vita-Salute San Raffaele, Milan, Italy.; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy., Cakir OO; Institute of Andrology, Department of Urology, University College London Hospitals NHS Trust, London, UK.; Division of Surgery and Interventional Science, UCL, London, UK., Castiglione F; Institute of Andrology, Department of Urology, University College London Hospitals NHS Trust, London, UK.; Division of Surgery and Interventional Science, UCL, London, UK., Alnajjar HM; Institute of Andrology, Department of Urology, University College London Hospitals NHS Trust, London, UK.; Division of Surgery and Interventional Science, UCL, London, UK., Muneer A; Institute of Andrology, Department of Urology, University College London Hospitals NHS Trust, London, UK.; Division of Surgery and Interventional Science, UCL, London, UK., Deho' F; ASST Sette Laghi-Circolo e Fondazione Macchi Hospital, Varese, Italy., Schifano F; Psychopharmacology; Drug Misuse; and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Herts, UK., Montorsi F; Università Vita-Salute San Raffaele, Milan, Italy.; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy., Salonia A; Università Vita-Salute San Raffaele, Milan, Italy. salonia.andrea@hsr.it.; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy. salonia.andrea@hsr.it.
Jazyk: angličtina
Zdroj: International journal of impotence research [Int J Impot Res] 2024 Feb; Vol. 36 (1), pp. 50-54. Date of Electronic Publication: 2022 May 21.
DOI: 10.1038/s41443-022-00583-3
Abstrakt: A range of drugs have a direct role in triggering ischaemic priapism. We aimed at identifying: a) which medications are associated with most priapism-reports; and, b) within these medications, comparing their potential to elicit priapism through a disproportionality analysis. The FDA Adverse Event Reporting System (FAERS) database was queried to identify those drugs associated the most with priapism reports over the last 5 years. Only those drugs being associated with a minimum of 30 priapism reports were considered. The Proportional Reporting Ratios (PRRs), and their 95% confidence intervals were computed. Out of the whole 2015-2020 database, 1233 priapism reports were identified, 933 of which (75.7%) were associated with 11 medications with a minimum of 30 priapism-reports each. Trazodone, olanzapine and tadalafil showed levels of disproportionate reporting, with a PRR of 9.04 (CI95%: 7.73-10.58), 1.55 (CI95%: 1.27-1.89), and 1.42 (CI95%: 1.10-1.43), respectively. Most (57.5%) of the reports associated with the phosphodiesterase type 5 inhibitors (PDE5Is) were related with concomitant priapism-eliciting drugs taken at the same time and/or inappropriate intake/excessive dosage. Patients taking trazodone and/or antipsychotics need to be aware of the priapism-risk; awareness among prescribers would help in reducing priapism-related detrimental sequelae; PDE5I-intake is not responsible for priapism by itself, when appropriate medical supervision is provided.
(© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: